[P1–394]: COMPARISON OF BASELINE ARIA‐H PREVALENCE AT 1.5T AND 3T MRI FIELD STRENGTHS IN A MULTI‐SITE GLOBAL CLINICAL TRIAL WITH COHORT OF 2137 AD SUBJECTS
Adam J. Schwarz(Eli Lilly (United States)), Eric Siemers(Eli Lilly (United States)), Jerome Barakos(Sutter Health), David Scott(Omneuron (United States)), Joonmi Oh(Biogen (United States)), Luc Bracoud(BioClinica (United States)), Christopher Carlson(Eli Lilly (United States)), Joyce Suhy(BioClinica (United States))
Cited by 1
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k